Oncology and Hematology - Global Oncology Academy

Episodes 177-192 of 532

SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Project Oncology®
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Project Oncology®
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
- Namrata Vijayvergia, MD
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
Project Oncology®
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
- Namrata Vijayvergia, MD
Diagnosing LCNEC of the Lung: Challenges and Strategies
Diagnosing LCNEC of the Lung: Challenges and Strategies
Project Oncology®
Diagnosing LCNEC of the Lung: Challenges and Strategies
- Junaid Arshad, MD, MS
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Project Oncology®
Personalizing Care for Large Cell Neuroendocrine Carcinoma
- Junaid Arshad, MD, MS
From Trials to Real-World Impact: CAR T-Cell Therapy for R/R Large B-Cell Lymphoma
From Trials to Real-World Impact: CAR T-Cell Therapy for R/R Large B-Cell Lymphoma
Project Oncology®
From Trials to Real-World Impact: CAR T-Cell Therapy for R/R Large B-Cell Lymphoma
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Matasar, MD
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
MinuteCE®
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
1.00 program credit
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 program credit
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
MinuteCE®
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
1.00 program credit
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 program credit
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
MinuteCE®
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
1.00 program credit
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 program credit
Analyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring
Analyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring
Project Oncology®
Analyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring
- Charles Turck, PharmD, BCPS, BCCCP
- Manali Kamdar, MD
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
CME/CE
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
0.50 credits
- Kevin Kalinsky MD, MS
- Komal Jhaveri, MD, FACP
0.50 credits
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Clinician's Roundtable
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Clinician's Roundtable
Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Project Oncology®
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Lunning, DO, FACP
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
- Aline Fares, MD

12/11